SCYNEXIS, Inc. Proceeds from License Fees Received
SCYNEXIS, Inc. (SCYX) reported Proceeds from License Fees Received of $500.00 thousand for the 1-month period ending 2014-01-31, per its 10-K filed 2016-03-07.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromLicenseFeesReceived · last filed 2020-03-11
- 2014-01-31: Proceeds from License Fees Received 1 month $500.00K.
- 2013-08-31: Proceeds from License Fees Received 1 month $1.50M.
- 2012-08-31: Proceeds from License Fees Received 1 month $313.00K.
| Period end | Proceeds from License Fees Received 1 month |
|---|---|
| 2014-01-31 | $500.00K 10-K · filed 2016-03-07 |
| 2013-08-31 | $1.50M 10-K · filed 2020-03-11 |
| 2012-08-31 | $313.00K 8-K · filed 2015-10-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |